Trends and Future Insights in the Immuno-Oncology Space


  • Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

lmmuno-oncology (IO) continues to be at the forefront of efforts to improve outcomes in cancer. BioPharma appears to be adopting a strategy of spreading its bets, doing many collaborations and outright deals to access potential combination programs, primarily as an add-on to a checkpoint inhibitor backbone. The complexity of building IO portfolios has increased as the number of clinical trials, in particular combination trials, has increased dramatically. The large number of promising options complicates clinical development and commercial strategies. The competition in the market and among clinical stage agents underscores the importance of trying to demonstrate differentiation and find the optimal positioning for novel agents. This talk will provide a snapshot of the latest trends In scientific and cllnlcal data and partnering deals, and overlay some vision Into the future of this dynamic space, the opportunities and the challenges, especially for early stage Blotech